ZA200308635B - 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders. - Google Patents

4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders. Download PDF

Info

Publication number: ZA200308635B
Authority: ZA; South Africa
Prior art keywords: methyl; ylidene; piperidin; quinolin; benzamide
Prior art date: 2001-05-18

Application number

ZA200308635A

Other languages

English (en)

Inventor

William Brown

Zhongyong Wei

Christopher Walpole

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-18

Filing date

2003-11-05

Publication date

2005-02-07

2003-11-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-02-07 Publication of ZA200308635B publication Critical patent/ZA200308635B/en

Links

230000036407 pain Effects 0.000 title claims description 9
208000018522 Gastrointestinal disease Diseases 0.000 title claims description 8
208000019901 Anxiety disease Diseases 0.000 title claims description 7
230000036506 anxiety Effects 0.000 title claims description 7
208000027520 Somatoform disease Diseases 0.000 title claims description 4
208000027753 pain disease Diseases 0.000 title claims description 4
TZKLMPPHEAGFJR-UHFFFAOYSA-N 4-[phenyl(piperidin-4-ylidene)methyl]benzamide Chemical class C1=CC(C(=O)N)=CC=C1C(C=1C=CC=CC=1)=C1CCNCC1 TZKLMPPHEAGFJR-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 48
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
-1 NOj Chemical group 0.000 claims description 13
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
230000002829 reductive effect Effects 0.000 claims description 11
125000001072 heteroaryl group Chemical group 0.000 claims description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
208000002193 Pain Diseases 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 7
238000000034 method Methods 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 5
125000002541 furyl group Chemical group 0.000 claims description 5
125000004076 pyridyl group Chemical group 0.000 claims description 5
125000000168 pyrrolyl group Chemical group 0.000 claims description 5
125000001246 bromo group Chemical group Br* 0.000 claims description 4
125000001309 chloro group Chemical group Cl* 0.000 claims description 4
125000001153 fluoro group Chemical group F* 0.000 claims description 4
125000002346 iodo group Chemical group I* 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
125000001544 thienyl group Chemical group 0.000 claims description 4
JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
229910052763 palladium Inorganic materials 0.000 claims description 3
KXJJSKYICDAICD-UHFFFAOYSA-N quinolin-8-ylboronic acid Chemical compound C1=CN=C2C(B(O)O)=CC=CC2=C1 KXJJSKYICDAICD-UHFFFAOYSA-N 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
101710198144 Endopolygalacturonase I Proteins 0.000 claims description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 2
101710191566 Probable endopolygalacturonase I Proteins 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
239000003054 catalyst Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000002883 imidazolyl group Chemical group 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
125000001425 triazolyl group Chemical group 0.000 claims description 2
VTPUSPHKJUMGJW-UHFFFAOYSA-N 4-[[1-(1h-imidazol-2-ylmethyl)piperidin-4-ylidene]-quinolin-8-ylmethyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC=2NC=CN=2)CC1 VTPUSPHKJUMGJW-UHFFFAOYSA-N 0.000 claims 1
BMXIFZALYMTOKZ-UHFFFAOYSA-N 4-[[1-(furan-2-ylmethyl)piperidin-4-ylidene]-quinolin-8-ylmethyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC=2OC=CC=2)CC1 BMXIFZALYMTOKZ-UHFFFAOYSA-N 0.000 claims 1
JFOCACBFZXCIAU-UHFFFAOYSA-N 4-[[1-(furan-3-ylmethyl)piperidin-4-ylidene]-quinolin-8-ylmethyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC2=COC=C2)CC1 JFOCACBFZXCIAU-UHFFFAOYSA-N 0.000 claims 1
DTCVFWAKOVXBHG-UHFFFAOYSA-N 4-[[1-[(4-methoxyphenyl)methyl]piperidin-4-ylidene]-quinolin-8-ylmethyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(OC)=CC=C1CN(CC1)CCC1=C(C=1C2=NC=CC=C2C=CC=1)C1=CC=C(C(=O)N(C(C)C)C(C)C)C=C1 DTCVFWAKOVXBHG-UHFFFAOYSA-N 0.000 claims 1
102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 claims 1
101710095312 Cytosolic 5'-nucleotidase 3A Proteins 0.000 claims 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
208000014540 Functional gastrointestinal disease Diseases 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
150000001860 citric acid derivatives Chemical class 0.000 claims 1
YZGOLGUSKFRMIL-UHFFFAOYSA-N n,n-di(propan-2-yl)-4-[[1-(pyridin-2-ylmethyl)piperidin-4-ylidene]-quinolin-8-ylmethyl]benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC=2N=CC=CC=2)CC1 YZGOLGUSKFRMIL-UHFFFAOYSA-N 0.000 claims 1
WHJYYDYAOWBMCT-UHFFFAOYSA-N n,n-di(propan-2-yl)-4-[[1-(pyridin-4-ylmethyl)piperidin-4-ylidene]-quinolin-8-ylmethyl]benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC=2C=CN=CC=2)CC1 WHJYYDYAOWBMCT-UHFFFAOYSA-N 0.000 claims 1
QIPDRKMSOSZWPQ-UHFFFAOYSA-N n,n-di(propan-2-yl)-4-[quinolin-8-yl-[1-(1,3-thiazol-2-ylmethyl)piperidin-4-ylidene]methyl]benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC=2SC=CN=2)CC1 QIPDRKMSOSZWPQ-UHFFFAOYSA-N 0.000 claims 1
RXOWNPHCYMWQJC-UHFFFAOYSA-N n,n-di(propan-2-yl)-4-[quinolin-8-yl-[1-(thiophen-2-ylmethyl)piperidin-4-ylidene]methyl]benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC=2SC=CC=2)CC1 RXOWNPHCYMWQJC-UHFFFAOYSA-N 0.000 claims 1
NYJUMEDNJYVJSZ-UHFFFAOYSA-N n,n-di(propan-2-yl)-4-[quinolin-8-yl-[1-(thiophen-3-ylmethyl)piperidin-4-ylidene]methyl]benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC2=CSC=C2)CC1 NYJUMEDNJYVJSZ-UHFFFAOYSA-N 0.000 claims 1
229940095064 tartrate Drugs 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
239000000543 intermediate Substances 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000000203 mixture Substances 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000007787 solid Substances 0.000 description 9
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
235000019439 ethyl acetate Nutrition 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000003756 stirring Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000000556 agonist Substances 0.000 description 5
239000012043 crude product Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
239000011734 sodium Substances 0.000 description 5
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000000730 antalgic agent Substances 0.000 description 4
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
239000012267 brine Substances 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
239000012317 TBTU Substances 0.000 description 2
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000002844 melting Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
UBOJYURSFIUEFZ-UHFFFAOYSA-N 2,3-di(propan-2-yl)benzamide Chemical compound CC(C)C1=CC=CC(C(N)=O)=C1C(C)C UBOJYURSFIUEFZ-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
NYYIGVYEDKYQEY-UHFFFAOYSA-N 4-[(1-benzylpiperidin-4-ylidene)-quinolin-8-ylmethyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C2=NC=CC=C2C=CC=1)=C1CCN(CC=2C=CC=CC=2)CC1 NYYIGVYEDKYQEY-UHFFFAOYSA-N 0.000 description 1
KQWVAUSXZDRQPZ-UMTXDNHDSA-N 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enyl-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide Chemical group C1=CC(C(=O)N(CC)CC)=CC=C1[C@H](C=1C=C(OC)C=CC=1)N1[C@@H](C)CN(CC=C)[C@H](C)C1 KQWVAUSXZDRQPZ-UMTXDNHDSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
ZXAPQWICZVMRRE-UHFFFAOYSA-N 4-[bromo-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-ylidene]methyl]benzoic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1=C(Br)C1=CC=C(C(O)=O)C=C1 ZXAPQWICZVMRRE-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000011688 Generalised anxiety disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000019430 Motor disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
208000020339 Spinal injury Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
229940124326 anaesthetic agent Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
INLLPKCGLOXCIV-UHFFFAOYSA-N bromoethene Chemical compound BrC=C INLLPKCGLOXCIV-UHFFFAOYSA-N 0.000 description 1
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000005961 cardioprotection Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
208000029364 generalized anxiety disease Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000007574 infarction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
IGTOJTIOIGZJBM-UHFFFAOYSA-N methyl 4-(dimethoxyphosphorylmethyl)benzoate Chemical compound COC(=O)C1=CC=C(CP(=O)(OC)OC)C=C1 IGTOJTIOIGZJBM-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
239000000842 neuromuscular blocking agent Substances 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000000047 product Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000036280 sedation Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000012265 solid product Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
LBTXNQJWUIPKNC-UHFFFAOYSA-N tert-butyl 4-[bromo-[4-[di(propan-2-yl)carbamoyl]phenyl]methylidene]piperidine-1-carboxylate Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(Br)=C1CCN(C(=O)OC(C)(C)C)CC1 LBTXNQJWUIPKNC-UHFFFAOYSA-N 0.000 description 1
BWUILNMXUUMHPV-UHFFFAOYSA-N tert-butyl 4-bromo-4-[bromo-(4-methoxycarbonylphenyl)methyl]piperidine-1-carboxylate Chemical compound C1=CC(C(=O)OC)=CC=C1C(Br)C1(Br)CCN(C(=O)OC(C)(C)C)CC1 BWUILNMXUUMHPV-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
208000009935 visceral pain Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

ZA200308635A 2001-05-18 2003-11-05 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders. ZA200308635B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0101767A SE0101767D0 (sv)	2001-05-18	2001-05-18	Novel compounds

Publications (1)

Publication Number	Publication Date
ZA200308635B true ZA200308635B (en)	2005-02-07

Family

ID=20284170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200308635A ZA200308635B (en)	2001-05-18	2003-11-05	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.

Country Status (25)

Country	Link
US (1)	US20040138259A1 (sv)
EP (1)	EP1395574B1 (sv)
JP (1)	JP2005507372A (sv)
KR (1)	KR20030094423A (sv)
CN (1)	CN1547579A (sv)
AR (1)	AR033756A1 (sv)
AT (1)	ATE287400T1 (sv)
BG (1)	BG108328A (sv)
BR (1)	BR0209667A (sv)
CA (1)	CA2446331A1 (sv)
CO (1)	CO5540304A2 (sv)
CZ (1)	CZ20033087A3 (sv)
DE (1)	DE60202679T2 (sv)
EE (1)	EE200300543A (sv)
HU (1)	HUP0401285A2 (sv)
IL (1)	IL158695A0 (sv)
IS (1)	IS7024A (sv)
MX (1)	MXPA03010438A (sv)
NO (1)	NO20035118D0 (sv)
PL (1)	PL366389A1 (sv)
RU (1)	RU2003131968A (sv)
SE (1)	SE0101767D0 (sv)
SK (1)	SK13932003A3 (sv)
WO (1)	WO2002094810A1 (sv)
ZA (1)	ZA200308635B (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CL2004000754A1 (es) *	2003-04-11	2005-02-25	Janssen Pharmaceutica Nv	Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
SE0301443D0 (sv) *	2003-05-16	2003-05-16	Astrazeneca Ab	Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
JP2007503457A (ja) *	2003-05-16	2007-02-22	アストラゼネカ・アクチエボラーグ	ジアリールメチリデンピペリジン誘導体、その製造およびその使用
WO2005005478A2 (en) *	2003-07-02	2005-01-20	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor; delta 1 (oprd1)
NZ546834A (en)	2003-10-01	2010-03-26	Adolor Corp	Spirocyclic heterocyclic derivatives and methods of their use
US7598261B2 (en)	2005-03-31	2009-10-06	Adolor Corporation	Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en)	2006-04-06	2009-08-18	Adolor Corporation	Spirocyclic heterocyclic derivatives and methods of their use
JP2010503669A (ja)	2006-09-12	2010-02-04	アドラーコーポレーション	認知機能の強化のためのｎ含有スピロ化合物の使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2898339A (en) *	1957-07-29	1959-08-04	Wm S Merrell Co	N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) *	1983-07-27	1986-04-08	Janssen Pharmaceutica, N.V.	[[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
US4816586A (en) *	1987-07-29	1989-03-28	Regents Of The University Of Minnesota	Delta opioid receptor antagonists
US5140029A (en) *	1989-01-09	1992-08-18	Janssen Pharmaceutica N.V.	2-aminopyrimidinone derivatives
US4939137A (en) *	1989-06-28	1990-07-03	Ortho Pharmaceutical Corporation	Ring-fused thienopyrimidinedione derivatives
US5683998A (en) *	1991-04-23	1997-11-04	Toray Industries, Inc.	Tricyclic triazolo derivatives, processes for producing the same and the uses of the same
US5574159A (en) *	1992-02-03	1996-11-12	Delta Pharmaceuticals, Inc.	Opioid compounds and methods for making therefor
TW548271B (en) *	1996-12-20	2003-08-21	Astra Pharma Inc	Novel piperidine derivatives having an exocyclic double bond with analgesic effects
US6436959B1 (en) *	1998-12-23	2002-08-20	Ortho-Mcneil Pharmaceutical, Inc.	4-[aryl(piperidin-4-yl)]aminobenzamides
SE0001207D0 (sv) *	2000-04-04	2000-04-04	Astrazeneca Canada Inc	Novel compounds

2001
- 2001-05-18 SE SE0101767A patent/SE0101767D0/sv unknown
2002
- 2002-05-16 JP JP2002591483A patent/JP2005507372A/ja active Pending
- 2002-05-16 HU HU0401285A patent/HUP0401285A2/hu unknown
- 2002-05-16 KR KR10-2003-7014944A patent/KR20030094423A/ko not_active Application Discontinuation
- 2002-05-16 DE DE60202679T patent/DE60202679T2/de not_active Expired - Fee Related
- 2002-05-16 AT AT02733703T patent/ATE287400T1/de not_active IP Right Cessation
- 2002-05-16 CZ CZ20033087A patent/CZ20033087A3/cs unknown
- 2002-05-16 CA CA002446331A patent/CA2446331A1/en not_active Abandoned
- 2002-05-16 EE EEP200300543A patent/EE200300543A/xx unknown
- 2002-05-16 BR BR0209667-6A patent/BR0209667A/pt not_active Application Discontinuation
- 2002-05-16 PL PL02366389A patent/PL366389A1/xx not_active Application Discontinuation
- 2002-05-16 EP EP02733703A patent/EP1395574B1/en not_active Expired - Lifetime
- 2002-05-16 AR ARP020101812A patent/AR033756A1/es not_active Application Discontinuation
- 2002-05-16 IL IL15869502A patent/IL158695A0/xx unknown
- 2002-05-16 RU RU2003131968/04A patent/RU2003131968A/ru not_active Application Discontinuation
- 2002-05-16 SK SK1393-2003A patent/SK13932003A3/sk unknown
- 2002-05-16 US US10/477,854 patent/US20040138259A1/en not_active Abandoned
- 2002-05-16 WO PCT/SE2002/000946 patent/WO2002094810A1/en not_active Application Discontinuation
- 2002-05-16 CN CNA02810191XA patent/CN1547579A/zh active Pending
- 2002-05-16 MX MXPA03010438A patent/MXPA03010438A/es unknown
2003
- 2003-11-05 ZA ZA200308635A patent/ZA200308635B/en unknown
- 2003-11-07 BG BG108328A patent/BG108328A/bg unknown
- 2003-11-11 IS IS7024A patent/IS7024A/is unknown
- 2003-11-12 CO CO03100160A patent/CO5540304A2/es not_active Application Discontinuation
- 2003-11-17 NO NO20035118A patent/NO20035118D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL366389A1 (en)	2005-01-24
BR0209667A (pt)	2004-04-20
CA2446331A1 (en)	2002-11-28
MXPA03010438A (es)	2004-03-09
IS7024A (is)	2003-11-11
RU2003131968A (ru)	2005-05-10
HUP0401285A2 (hu)	2004-12-28
CN1547579A (zh)	2004-11-17
SE0101767D0 (sv)	2001-05-18
ATE287400T1 (de)	2005-02-15
JP2005507372A (ja)	2005-03-17
US20040138259A1 (en)	2004-07-15
DE60202679D1 (de)	2005-02-24
EE200300543A (et)	2004-02-16
NO20035118D0 (no)	2003-11-17
CZ20033087A3 (cs)	2004-05-12
IL158695A0 (en)	2004-05-12
CO5540304A2 (es)	2005-07-29
BG108328A (bg)	2004-12-30
DE60202679T2 (de)	2006-03-30
WO2002094810A1 (en)	2002-11-28
EP1395574B1 (en)	2005-01-19
AR033756A1 (es)	2004-01-07
SK13932003A3 (sk)	2004-05-04
EP1395574A1 (en)	2004-03-10
KR20030094423A (ko)	2003-12-11

Publication	Publication Date	Title
EP1480954B1 (en)	2008-12-03	Vanilloid receptor modulators
FI90980B (sv)	1994-01-14	Förfarande för framställning av N-heterocykliska N-(4-piperidyl)-amider
US20080004288A1 (en)	2008-01-03	Indazole Sulphonamide Derivatives
CZ20011760A3 (cs)	2001-12-12	Pyrrolidinové deriváty jako antagonisty CCR-3 receptorů
UA72319C2 (en)	2005-02-15	Pharmaceutical compositions containing 3-aminoazetidine derivatives, derivatives and a method for obtaining thereof
SK283211B6 (sk)	2003-03-04	Piperidínové zlúčeniny s analgetickým účinkom, spôsob ich prípravy, medziprodukty na ich prípravu, ich použitie, diagnostické činidlo a farmaceutické kompozície s ich obsahom
SK283300B6 (sk)	2003-05-02	Piperidínové zlúčeniny s analgetickým účinkom, spôsob ich prípravy, medziprodukty na ich prípravu, ich použitie, diagnostické činidlo a farmaceutické kompozície s ich obsahom
ZA200308633B (en)	2005-02-07	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.
JP6906449B2 (ja)	2021-07-21	複素環スルホンアミド誘導体及びそれを含有する医薬
ZA200308634B (en)	2005-05-25	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders.
CA2393568C (en)	2009-08-18	Diarylmethylpiperazines
ZA200308635B (en)	2005-02-07	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.
TW200418822A (en)	2004-10-01	Novel compounds
KR101386318B1 (ko)	2014-04-17	히스타민 ｈ3 수용체의 길항제로서의 이소퀴놀린 및 벤조［ｈ］이소퀴놀린 유도체, 그의 제조 및 치료 용도
SK14242002A3 (sk)	2003-06-03	Chinolinylpiperidin-4-ylidénmetylbenzamidové deriváty na liečbu bolesti
ZA200308636B (en)	2005-06-21	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.
JP4943826B2 (ja)	2012-05-30	医薬組成物
JP4760139B2 (ja)	2011-08-31	ピロリジン誘導体およびその製法
EP1603899B1 (en)	2009-08-26	Heterocyclic urea derivatives for the treatment of pain
JP2006519806A (ja)	2006-08-31	尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。
JP2009513513A (ja)	2009-04-02	Ｏｒｌ−１受容体リガンドとしての置換インドール
WO2006033627A1 (en)	2006-03-30	Compounds, compositions containing them, preparation thereof and uses thereof iiii
WO2004078101A2 (en)	2004-09-16	Urea derivatives having vanilloid receptor antagonist activity
CZ20033089A3 (en)	2004-06-16	4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
ZA200308637B (en)	2005-02-07	4-[Phenyl-(piperidin-4-yl)-amino]-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.